Experimental cell therapy takes on Hard-to-Treat cancers

NCT ID NCT04898543

Ongoing Disease control Sponsor: ImmunityBio, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study is testing a new treatment for people with advanced solid tumors that have spread. The treatment uses a patient's own immune cells, called M-CENK, which are collected, processed, and given back along with a booster drug called N-803. The main goal is to see if the approach is safe, with 50 participants split into two groups based on how many prior treatments they have had.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M-CENK (a type of immune cell) and N-803 (a drug that boosts immune cells)
What this could lead to: If this works, it could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety, not effectiveness. The treatment may not shrink tumors or improve survival, and there are risks of side effects like cytokine release syndrome.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metastatic malignant neoplasm Neoplasm Metastasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOLID TUMOR

Contacts and locations

Locations

Chan Soon-Shiong Institute for Medicine

El Segundo, California, 90245, United States
Hoag Memorial Hospital Presbyterian

Newport Beach, California, 92663, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.